VSV-IFN-β treatment increased the generation of anti-tumor T cell populations, thereby significantly enhancing the efficacy of immune checkpoint inhibitors (ICIs) like anti-PD1 antibodies [4]. The gene discussed is IFNB1; the disease is neoplasm.